Old and new applications of non-anticoagulant heparin

Cassinelli, Giuseppe; Naggi, Annamaria

doi:10.1016/s0167-5273(16)12004-2

Cited by 71 publications

(71 citation statements)

References 122 publications

(148 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…41 In addition, over recent years, the activity and functional role of NAC heparins in different forms have been widely investigated, including in angiogenesis and pulmonary diseases. [42][43][44] The antiinflammatory role, via inhibition of leukocyte infiltration, 45 and antimetastatic role in lung and colon 46 and pancreatic cancer cells 47 of these NAC heparins has also been established. However, their efficacy and safety in pregnancy have not been investigated.…”

Section: Discussionmentioning

confidence: 99%

Antiangiogenic effects of decorin restored by unfractionated, low molecular weight, and nonanticoagulant heparins

et al. 2017

View full text Add to dashboard Cite

Key Points• UFH, LMWH, and NAC restored angiogenesis in decorin-reduced endothelial cells.• NAC treatment was similar to, or better than, UFH or LMWH at improving endothelial angiogenesis without increasing anticoagulant activity.Pregnancies affected by preeclampsia (PE) or fetal growth restriction (FGR) display increases in thrombin generation and reductions in angiogenesis and cell growth. There is significant interest in the potential for low molecular weight heparins (LMWHs) to reduce the recurrence of PE and FGR. However, LMWH is associated with an increased risk of bleeding. Therefore, it is of vital importance to determine the exact molecular function of heparins in pregnancy if they are used as therapy for pregnant women. We aimed to determine this using our model Therefore, NAC could potentially be a better therapeutic option for prevention of PE/FGR in high-risk women, without the risk of the adverse effects of traditional anticoagulants.

show abstract

Section: Discussionmentioning

confidence: 99%

Antiangiogenic effects of decorin restored by unfractionated, low molecular weight, and nonanticoagulant heparins

et al. 2017

View full text Add to dashboard Cite

show abstract

“…46 Not only that, but it can also provide shielding properties when used to coat numerous types of nanoparticles. 47–51 One study found that low molecular weight heparin coating improved the biological properties of mesoporous nanoparticles by preventing recognition and uptake by macrophages.…”

Section: Bio-inspired Shielding Strategiesmentioning

confidence: 99%

Bioinspired Shielding Strategies for Nanoparticle Drug Delivery Applications

Gulati

Stewart²,

Steinmetz³

2018

Mol. Pharmaceutics

View full text Add to dashboard Cite

Nanoparticle delivery systems offer advantages over free drugs, in that they increase solubility and biocompatibility. Nanoparticles can deliver a high payload of therapeutic molecules while limiting off target side effects. Therefore, delivery of an existing drug with a nanoparticle frequently results in an increased therapeutic index. Whether of synthetic or biologic origin, nanoparticle surface coatings are often required to reduce immune clearance and thereby increase circulation times allowing the carriers to reach their target site. To this end, polyethylene glycol (PEG) has long been used, with several PEGylated products reaching clinical use. Unfortunately, the growing use of PEG in consumer products has led to an increasing prevalence of PEG-specific antibodies in the human population, which in turn has fueled the search for alternative coating strategies. This review highlights alternative bio-inspired nanoparticle shielding strategies, which may be more beneficial moving forward than PEG and other synthetic polymer coatings.

show abstract

“…[9][10][11][12] The therapeutic potential of heparin is vast, and the clinical evidence includes treatment for fibrosis, infectious diseases, inflammatory diseases, and cancer, among others. [9][10][11][12] The therapeutic potential of heparin is vast, and the clinical evidence includes treatment for fibrosis, infectious diseases, inflammatory diseases, and cancer, among others.…”

Section: Heparin Has Broad Clinical Potentialmentioning

confidence: 99%

Glycan Therapeutics: Resurrecting an Almost Pharma‐Forgotten Drug Class

Paderi¹,

Prestwich

Panitch

et al. 2018

Advanced Therapeutics

View full text Add to dashboard Cite

Despite their enormous potential, glycans as therapeutics yet remain a widely untapped drug class. This overview shares the viewpoint that glycans have been aptly termed the "dark matter" of biology and have thus been largely ignored for decades. Provided herein is a background on the multiple structures and functions of glycan therapeutics, and focuses on examples and case studies of the glycan therapeutics in clinical use or in a clinical development. Perspectives on various hurdles are also provided, such as regulatory or scientific messaging and how these can influence the clinical development of this drug category. Finally some of the necessary changes in perception, education, and research infrastructure for continued support and advancement of this promising category of therapeutics are described.

show abstract

Old and new applications of non-anticoagulant heparin

Cited by 71 publications

References 122 publications

Antiangiogenic effects of decorin restored by unfractionated, low molecular weight, and nonanticoagulant heparins

Antiangiogenic effects of decorin restored by unfractionated, low molecular weight, and nonanticoagulant heparins

Bioinspired Shielding Strategies for Nanoparticle Drug Delivery Applications

Glycan Therapeutics: Resurrecting an Almost Pharma‐Forgotten Drug Class

Contact Info

Product

Resources

About